Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018026819) TREATMENT OF CANCER USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH AN INHIBITOR OF A PRO-M2 MACROPHAGE MOLECULE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/026819 International Application No.: PCT/US2017/044909
Publication Date: 08.02.2018 International Filing Date: 01.08.2017
IPC:
A61K 39/00 (2006.01) ,C07K 16/24 (2006.01) ,C07K 16/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
24
against cytokines, lymphokines or interferons
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel, CH
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chesnut Street, Suite 200 Philadelphia, PA 19104, US
Inventors:
GILL, Saar; US
RUELLA, Marco; US
KLICHINSKY, Michael; US
Agent:
COLLAZO, Diana, M.; US
KOYFMAN, Hannah, R.; US
LU, David; US
ADAMS, Melissa, M.; US
Priority Data:
62/369,58901.08.2016US
Title (EN) TREATMENT OF CANCER USING A CHIMERIC ANTIGEN RECEPTOR IN COMBINATION WITH AN INHIBITOR OF A PRO-M2 MACROPHAGE MOLECULE
(FR) TRAITEMENT DU CANCER AU MOYEN D'UN RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE EN COMBINAISON AVEC UN INHIBITEUR D'UNE MOLÉCULE DE MACROPHAGE PRO-M2
Abstract:
(EN) The invention provides compositions and methods for treating diseases associated with expression of an antigen, e.g., a solid tumor antigen or antigen expressed on a tumor associated with TAMs and/or MDSCs, by administering a recombinant T cell comprising a CAR binding to said antigen, as described herein, in combination with an inhibitor of a pro-M2 macrophage molecule, e.g., described herein. The invention also provides kits and compositions described herein.
(FR) L'invention concerne des compositions et des procédés pour traiter des maladies associées à l'expression d'un antigène, par exemple, un antigène de tumeur solide ou un antigène exprimé sur une tumeur associée à des MAT et/ou des MDSC, par administration d'un lymphocyte T recombiné comprenant un CAR se liant audit antigène, de l'invention, en combinaison avec un inhibiteur d'une molécule de macrophage pro-M2, par exemple, de l'invention. L'invention concerne également des kits et des compositions de l'invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)